Morphine sulfate is the generic version of a tablet that contains morphine, an addictive and potent drug that is used to relieve moderate to severe pain. It is prescribed primarily for cancer patients. Morphine sulfate comes in either immediate release or extended release tablets.
On November 7, 2008, the FDA posted a press release from ETHEX Corporation announcing the recall of its generic/non-branded morphine sulfate tablets in the following lots:
Morphine Sulfate Extended Release Tablets, 15 mg: Lots: 81175, 82514-16, 89660, 89664, 89667, 90249-51, and 91687 with expiration dates ranging from 12/2008 to 2/2010
Morphine Sulfate Immediate Release Tablets, 15 mg: Lots: 77852-54, 81746, 82519-20, 84113, and 90276-78 with expiration dates ranging from 9/2009 to 1/2011
Morphine Sulfate Immediate Release Tablets, 30 mg: Lots: 75093, 77855-57, 82297, 82521-22, 87239, 88925, and 90288-98 with expiration dates ranging from 8/2009 to 3/2011
These lots were recalled as a precaution, as they may contain oversized tablets, which could result in patients receiving up to twice the recommended dosage. These patients could experience some serious side effects, and even risk death. Morphine sulfate tablet overdose side effects could include respiratory depression (difficulty or lack of breathing) and low blood pressure.
According to the ETHEX Corporation press release, "The 15 mg Morphine Sulfate Extended Release Tablet is a green oval tablet with "15" on one side and an "E" on the reverse. The 15 mg Morphine Sulfate Immediate Release Tablet is a round brown tablet with a "15" on one side and an "ETH" on the reverse. The 30 mg Morphine Sulfate Immediate Release Tablet is a capsule shaped brown tablet with "30" on one side and an "ETHEX" on the reverse."
ETHEX Corporation sent its recall notifications to wholesalers and retailers that received inventory of the morphine sulfate lots with the possible oversized tablets. The recall notices give instructions for retailers and pharmacies to contact consumers given this medication in order that they may either get replacement of the product or a refund.
Consumers who experience any adverse reactions to morphine sulfate tablets listed in the lot numbers above should contact their healthcare providers immediately.
If you or a family member has taken morphine sulfate tablets from the lot numbers above, and experienced adverse side effects or died as a result, please fill out our Case Review Form to the right on this page for a free consultation.
Dangerous Drugs
News Articles
Pfizer Starts Media Ad Blitz to Address Smoking Drug Concerns
May 28 (Bloomberg) – Pfizer Inc.
(read more..)
North Carolina Case Claims Financial Calamity From Bayer Drug
5/2/08 - Triangle Business Journal
(read more..)
Panel May Issue Subpoenas Related to FDA Approval
on Antibiotic Drug Ketek
1/28/08 - FDA
(read more..)
Second Safety Warning on Fentanyl Skin Patch
12/21/07 - FDA
(read more..)
F.D.A. Investigates Quit-Smoking Drug
11/20/07 - Associated Press
(read
more..)
Merck to Pay $4.85 Billion To Settle Most Vioxx Cases
11/09/07 - AngelReyesBlog.com
(read
more..)
Cephalon Drug Is Tied to Several Deaths
9/14/07 - The Wall Street Journal
(read
more..)
$5.5 Million Award in First Federal Fentanyl (Duragesic) Pain Patch Trial
6/19/07 - Press Release
(read
more...)